Slide 1: Corporate Presentation
Corporate Presentation September 2026 Bringing hope to people living with Neurodegenerative diseases 1 www.alphacognition.com
Slide 2: Forward-looking statements
Forward-looking statements This presentation has been prepared by Alpha Cognition Inc. (“ACI” or the “Company”). This presentation includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this present
Slide 3: Investment highlights
Investment highlights Corporate Profile ZUNVEYL® Commercial Launch Alpha Cognition is a First oral Alzheimer’s (AD) treatment approved in 15 years commercial stage bio- pharmaceutical company Over 25,000 prescriptions filled through first 5 quarters of launch committed to developing Q2 2026 revenues
Slide 4: ZUNVEYL: novel galantamine prodrug
ZUNVEYL: novel galantamine prodrug The formation of the benzoyl ester eliminates AChE inhibition; the gluconate Galantamine salt increases solubility Prodrug Design: ZUNVEYL is absorbed in the small Optimized intestine as an inactive compound efficacious dose with minimal side effects Minimize ZUNVE
Slide 5: Galantamine enhances acetylcholine levels & modulates nicotinic receptor sensitivity
Galantamine (ZUNVEYL’s active moiety) enhances acetylcholine levels & modulates nicotinic receptor sensitivity First Oral Alzheimer’s (AD) treatment approved by FDA in 15 years • Dual MOA – Acetylcholinesterase Inhibitor (AChEI) & modulates alpha nicotinic receptor sensitivity • Effective for AD cog
Slide 6: Commercial strategy focuses on high volume LTC market
Commercial strategy focuses on Prescriptions by Specialty1 high volume LTC market 5% Attractive Commercial TAMs Psych • LTC provides large $2B potential commercial opportunity3 , 29% represents 41% of total market Neuro • Approximately 70% of residents have AD • Brand medications used more commonly
Slide 7: ZUNVEYL's differentiated profile offers compelling alternative to existing therapies
ZUNVEYL’s differentiated profile offers compelling alternative to existing therapies New treatment paradigm Significant need for better treatment options Designed to avoid GI nervous system stimulation Purposefully Designed Protects from peripheral and central cholinergic Prodrug Technology Side Eff
Slide 8: Commercialization strategy leverages LTC experience & focused sales effort to key customers
Commercialization strategy leverages ~5,000 LTC experience & focused sales effort to Nursing home targets key customers Over 3,200 calls to nursing homes in Q2 ~3,000 Health Care Provider (HCP) targets Over 8,100 calls to HCP targets in Q2 60 50 sales representatives 10 field and payor support 8
Slide 9: Prescriptions and prescribers continue to grow
Prescriptions and prescribers continue to grow 8,294 ▲ +37% vs. 1Q26 1,900+ cumulative prescribers Filled prescriptions per quarter Cumulative prescribers by month 9,000 1,600 8,294 8,000 1,400 1,347 7,000 1,200 6,054 1,069 6,000 1,000 4,941 855 5,000 800 4,000 661 3,106 600 3,000 370 400 2,000 1,54
Slide 10: Early payor coverage contracts secured for ZUNVEYL
Early payor coverage contracts secured for ZUNVEYL 45% 90% Potential Medicare Of prescriptions currently Coverage approved with Alpha Cognition reimbursement support >25M Potential Medicare lives Reimbursement team coverage without Prior Authorization (PA)1 Expansion to manage VOLUME GROWTH WITH PA’
Slide 11: Key performance indicators as of Q2 2026
Key performance indicators as of Q2 2026 NET PRODUCT FILLED CUMULATIVE HCP REPEAT REVENUE PRESCRIPTIONS (Q) PRESCRIBERS (LTD) PRESCRIBERS $6M 8,294 1,908 76% ▲ +71% Q/Q ▲ +37% Q/Q ▲ +29% Q/Q of Q2 writers HCP HOMES WITH PRESCRIBERS PRODUCT PRESCRIBERS (Q) RX (Q) CALLED ON (Q) GROSS MARGIN 1,347 1,09
Slide 12: Financial highlights as of Q2 2026
Financial highlights as of Q2 2026 Net product revenue ($M) Operating expenses ($M) $7.0 $16.0 $6.0 $13.5 $6.0 $14.0 CASH & EQUIVALENTS $5.0 $12.0 $11.4 $41.4M As of June 30, 2026 $10.0 $4.0 $3.5 $8.0 $8.0 $7.5 $3.0 $2.3 $2.5 $50–54M $6.0 $2.0 Full-year 2026 $4.0 operating expense $1.0 guidance $2.0
Slide 13: Multiple lifecycle and label-expansion programs ahead
Multiple lifecycle and label-expansion programs ahead PRECLINICAL IND / PHASE 1 PHASE 2 / 3 FILED/APPROVED COMMERCIAL STATUS / TIMING ON MARKET Approved & launched COMMERCIAL ZUNVEYL — mild-to-moderate AD Over 25,000 prescriptions filled GEOGRAPHIC EXPANSION UNDER REVIEW ZUNVEYL — ex-US (Asia) Under
Slide 14: Three differentiating clinical studies support ZUNVEYL strategy
Three differentiating clinical studies support ZUNVEYL strategy Interventional trial in AD Retrospective data analysis Real-world effectiveness patients with behaviors in long-term care AD study in long-term care patients Evaluation of ZUNVEYL Analysis of ZUNVEYL in the LTC Evaluation of ZUNVEYL tol
Slide 15: Potential catalysts and upcoming events
Potential catalysts and upcoming events Q3 2026 Q4 2026 H1 2027 2H 2027 Sublingual PK Study Sublingual IND for RESOLVE Topline Study Sublingual Pivotal Trial for Completion Alzheimer’s Disease (AD) Results AD Topline Results Sublingual IND for ZUNVEYL Approval in 2 ex- TBI Toxicity Study Alpha Cogni
Slide 16: Leadership has impressive track record for successful new drug development & commercialization
Leadership has impressive track record for successful new drug development & commercialization Michael McFadden Chief Executive Officer 30+ years in drug discovery & commercialization (16+ years in Neuroscience) Former COO at MPower Health and Urovant Sciences (acquired by Sumitovant Biopharma for $
Slide 17: Share capitalization
Share capitalization NASDAQ: ACOG Issued and % of Total Key Data Points Outstanding As of 8/10/2026 (as of August 10, 2026, except where noted) Common Shares 21,777,868 72.9% Ticker ACOG Class B Preferred Series A Shares 316,655 1.1% Stock Price $8.89 Issued & % of total Performance Shares Outstandi
Slide 18: Investment highlights
Investment highlights Corporate Profile ZUNVEYL® Commercial Launch Alpha Cognition is a First oral Alzheimer’s (AD) treatment approved in 15 years commercial stage bio- pharmaceutical company Over 25,000 prescriptions filled through first 5 quarters of launch committed to developing Q2 2026 revenues
Slide 19: Investor Relations
Investor Relations pjkelleher@lifesciadvisors.com ir@alphacognition.com www.alphacognition.com
Slide 20: What Is A Mild Traumatic Brain Injury (mTBI) And Cognitive Impairment?
What Is A Mild Traumatic Brain Injury (mTBI) And Cognitive Impairment? An mTBI occurs when a head injury disrupts brain function CAUSES FALLS VEHICLE RELATED VIOLENCE SPORTS INJURIES COMBAT INJURY CONCUSSIONS mTBI can cause a wide range Cognitive Impairment: short-term memory loss, trouble concentra
Slide 21: Cognitive Impairment With mTBI Represents Significant $10.8B+ Market Opportunity
Cognitive Impairment With mTBI Represents Significant $10.8B+* Market Opportunity Total Addressable Citizens who live with a permanent Available Market Market +5.0M brain injury-related disability US TBI diagnosed 3.0M events in 2019 1.4M 2.7M per year per year Annual TBI-related ER visits4*, 2.8M h
Slide 22: ALPHA-1062IN Scientific Rationale To Treat Cognitive Impairment With mTBI
ALPHA-1062IN Scientific Rationale To Treat Cognitive Impairment With mTBI Mechanism: Alpha7-Nicotinic Pre-clinical and clinical modulation and ACHE inhibition experience with ALPHA-1062IN • Alpha-7 modulation affects improves brain receptor • Pre-clinical data demonstrated pronounced transmission, w
Slide 23: ALPHA-1062 Opportunity
ALPHA-1062 Opportunity Large, Underserved Symptom Focus Excellent Rationale Upcoming Market Improves Opportunity For Efficacy Milestones 1.4M with Cognitive Targeting Cognitive Modulates A7 Receptor Regulatory alignment Impairment following Impairment, a key which is implicated in with FDA TBI annua